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Abstract 
Purpose: To search for novel scaffolds as potential inhibitors of 3CLpro protease enzyme and as 
antiviral drugs. 
Methods: NCI database was screened using structure-based pharmacophore modeling, database 
screening and molecular docking. Also, Lipininski’s rule of 5 was applied in order to test the drug-
likeness of the retrieved compound.  Pharmacophore modelling and subsequent post-docking analyses 
were used for comparison of the binding mode of the retrieved hits with that of the x-ray inhibitor, R30, 
against MERS-CoV 3CLpro enzyme. 
Results: Five compounds were identified as potential agents for the treatment of corona virus, MERS-
CoV, which showed similar binding to MERS-CoV 3CLpro like that of the x-ray inhibitor, R30. As 
protease enzyme plays an indispensable role during virus life cycle, CoV 3CLpro has been reported as 
a highly validated drug target and it is considered viable for the design of broad spectrum inhibitors. The 
selected five hit compounds bind to MERS-CoV 3CLpro in a manner similar to that of the x-ray inhibitor, 
R30, and showed pharmacophore-fit and docking score values higher than those of R30, MERS-CoV 
3CLpro-inhibitor.  
Conclusion: The retrieved five hits are proposed as new scaffolds for further evaluation and 
optimization of their activity against MERS-CoV. 
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In June 2012, the Middle East respiratory 
syndrome coronavirus (MERS-CoV) was first 
diagnosed from a Saudi Arabian patient who had 
died from progressive respiratory and renal 
failure [1]. Up to July 2015, it had infected at least 
1401 people with a fatality rate surpassing 39 % 
[2].  Recent reports have confirmed the human-
to-human transmission of MERS-CoV. Thus, 
prompt efforts are necessary to develop new 
antiviral drugs or therapy for treatment of MERS-
CoV. 
 
Protease enzyme is essential for viral replication 
by mediating the maturation of viral replicase 
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polyprotein by the viral papain-like protease 
(PLpro) and the 3-chymotrypsin-like protease 
(3CLpro) thus, these proteases become 
alternative targets for potential antiviral drugs. 
Since the 3CLpro and PLpro enzymes are 
unique in the virus, present only in the virus and 
not in the host cell, this therapeutic strategy 
appears to be much safer than the one that 
targets host cell proteins [3,4]. Viral proteases, 
including the papain-like protease (PLpro) and 
the main protease 3C-like protease (3CLpro), 
process the replication of the genomic RNA of 
MERS coronavirus.  
 
Since 2012, there are no effective antiviral 
therapeutic against human coronaviruses, 
including MERS-CoV but only primary organ 
support for respiratory and renal failure were the 
only clinical management of the infection. Use of 
broad-spectrum antivirals including antiviral 
agents against influenza, has also been 
recommended [5]. Treatment with interferon has 
also been suggested as a promising therapeutic 
strategy against MERS-CoV [6]. In 2013, first 
generation of protease inhibitor antiviral drugs, 
such as N3 [3] and CE-10 [7] that were optimized 
for inhibition of SARS-CoV 3CLpro have been 
reported to block the activity of MERS-CoV 
3CLpro. Some SARS-CoV 3CLpro 
peptidomimetics which contains a Michael 
acceptor, (i.e., α,β-unsaturated carbonyl) [1], or 
contains activated carbonyl functionality 
displayed inhibition against MERS-CoV 3CLpro.  
 
In view of these findings there is still a need for 
novel potent MERS-CoV inhibitors. Traditional 
synthesis and screening of a series of new 
compounds is well known as cost and time 
consuming process. On the other hand, an 
alternative process can be used by applying in 
silico screening of small molecule databases for 
novel compounds. Dependent on the amount of 
information available, either ligand-based or 
structure-based molecular design can be applied 
to find lead molecules [8]. In this work we 
describe screening a set of compounds from 
National Cancer Institute (NCI) database against 
MERS-CoV 3CLpro protein, with bound ligand 
R30 [9], by utilizing a ligandScout program [10] 




Preparation of the protein structure and 
ligand structures 
 
The National Cancer Institute (NCI) database, a 
free database for virtual screening, contains 
about 250,250 compounds in 3D formats. The x-
ray crystal structure of MERS-CoV 3CLpro 
bound by the ligand, N-{4-[(1H-benzotriazol-1-
ylacetyl)(thiophen-3-ylmethyl)amino]phenyl}pro-
panemide (R30), was obtained from the Protein 
Data Bank (PDB code: 4YLU) [9]. The 
undertaken molecular modelling works were 
done on PC Windows 7 Home Premium Intel(R) 
Core(TM)2 Duo, 1.83GHz.  
 
Structure-based pharmacophore building 
 
The spatial arrangement of atoms or functional 
groups, called a pharmacophore, suggests how a 
ligand molecule can interact inside the binding 
site of a target protein.  
 
The pharmacophore theory is based on the fact 
that ligand molecules that have the same 
biological binding site, should have common 
pharmacophore [12]. Based on the available 
information of ligands and the target 
macromolecule, there are two pharmacophore 
modelling approaches. The ligand-based 
approach is carried out by extracting common 
spatial arrangement of the chemical features of a 
set of known ligands postulated to have same 
binding mode to a specific target protein. While, 
the structure based approach demands 
necessitates the 3D structure of a target 
molecule or a macromolecule–ligand complex.  
Using LigandScout program [10], the latter 
approach was utilized to build a pharmacophore 
model making use of the x-ray crystal structure of 
MERS-CoV 3CLpro bound with inhibitor 
compound R30 (PDB code: 4YLU) [9]. In this 
study, the pharmacophore model is obtained 
through the investigation of the complementary 
chemical features of the binding site and their 




The coordinates of the x-ray structure of the 
MERS-CoV 3CLpro (4YLU) bound to its ligand 
(R30) were got from the Protein Data Bank 
(PDB) [9]. The x-ray ligand was redocked into its 
binding pocket to examine whether the docked 
pose could have same orientation as the x-ray 
ligand indicating the validity of the parameters in 
the docking simulation and in reproducing the x-
ray crystal structure. The AutoDock Vina 
program was used for molecular docking-based 




The coordinate files of ligands datasets in the 
NCI database are filtered by Lipinski’s rule. Only 
the molecules which in accordance with 
Lipinski’s rule can be considered as hits, 
retrieved from NCI database and grouped in a 
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chemical library. The obtained library was 
subjected to virtual screening using structure-
based pharmacophore model resulting in a 
reduced size chemical library. The candidates in 
the obtained library were ranked based on 
docking score using AutoDock Vina program. 
Top ranked candidates were suggested for 
experimental screening as potential therapeutic 




Lipinski’s rule of 5 was used for filtering the NCI 
database (250,250 entries) and identified a 
reduced diversity subset including 3120 small 
molecules that were subjected to further 
screening, using macromolecule-ligand-complex-
based pharmacophore model (Figure 1 and 





Figure 1: Schematic representation of the structure-
based virtual screening work-flow 
 
Docking study was undertaken in order to screen 
the hits retrieved from virtual screening using the 
pharmacophore query. The target 
macromolecule file (PDB ID: 4YLU) was obtained 
from PDB (www.rcsb.org) and explored the 
binding mode of peptide-like-inhibitor, N-{4-[(1H-
benzotriazol-1-ylacetyl)(thiophen-3-
ylmethyl)amino]phenyl}propanamide, R30, in the 




Figure 1 shows the schematic representation of 
screening workflow. Lipinski's Rule of Five 
describes the molecular characteristics crucial for 
in vivo drug's pharmacokinetics, involving their 
absorption, distribution, metabolism, and 
elimination (ADME). The rule determines 
whether a biologically-active molecule would be 
a likely orally active drug or not. First, Lipinski’s 
rule of 5 was used for filtering the NCI database 
(250,250 entries) and identified a reduced 
diversity subset including 3120 small molecule. 
We screened these 3120 compounds using 
macromolecule-ligand-complex-based pharma-
cophore modelling. Using the 3D structure of the 
MERS-CoV 3CLpro-ligand complex (4YLU.pdb), 
LigandScout program analyse the spatial 
arrangement of the matching chemical 
characteristics of the binding site and design a 
pharmacophore model with the selected 
features. The resulting pharmacophore model is 
composed of four features including two 
hydrophobes, one hydrogen acceptor, and one 




Figure 2: The macromolecule-ligand-complex-based 
pharmacophore model shows two hydrophobes (a), 
one hydrogen acceptor (b) and one hydrogen donor 
(c) 
 
Table 1: Binding energy (Kcal/mol) and hydrogen 










NSC648199 -8.7 2 Gln167, 
Phe143 
NSC159375 -8.3 1 Glu169 
NSC29007 -8.1 1 Gly146 
NSC335985 -8.1 2 Ser147, 
Glu169 
NSC337571 -7.8 0  
R30 (x-ray 
ligand) 














Figure 4: The 3D diagrams of interaction between the 
MERS-CoV 3CLpro and the five hit compounds 
overlaid on R30 x-ray ligand (colored black). The 
dotted lines show the hydrogen bond between the 
compounds and the binding. 
 
Based on the pharmacophore fit value, the top 
109 ligands were suggested for further screening 
using AutoDock Vina program. The AutoDock 
Vina algorithm searches different orientations of 
the compounds inside the binding site of 
receptor. Rely on the binding energy scores, five 
ligands were selected, NSC159375, NSC29007, 
NSC337571, NSC335985, NSC648199 (Table 1, 
Figure 3) were having lower energy scores than 
that R30 (xray ligand) which reveal promising 
binding affinity towards the active site of MERS-
CoV 3CLpro. These ligands might act as 
potential inhibitors for the MERS-CoV 3CLpro 
and were suggested for experimental screening. 
 
Docking study was undertaken using AutoDock 
Vina in order to screen the hits retrieved from 
virtual screening using the structure-based 
pharmacophore model. Also, the possible 
interactions between the top-score ranked hits 
and the active site of the MERS-CoV 3CLpro 
were compared with the binding mode of the 
known 4YLU peptide-like-inhibitor, N-{4-[(1H-
benzotriazol-1-ylacetyl)(thiophen-3-
ylmethyl)amino]phenyl}propanamide, R30. R30 
has a tricyclic structure and is oriented in its 
binding site that is lined with the side chains of 
Met25, His41, Ala46, Leu49, Tyr54, Phe143, 
Cys148, His166, Met168, Glu169, Asp190, 
Gln192 (Figure 4, Table 1). 
 
One of the nitrogen atoms of the benzotriazole 
moiety form hydrogen bond to the imidazole-
nitrogen of His166, while the carbonyl oxygen of 
the acetyl moiety from a hydrogen bond to the 
amide-nitrogen of Glu169. Replication of the 
binding mode of the bound inhibitor, R30, by the 
docking algorithm used in the virtual screen 
would indicate that it is well calibrated for this 




A computational approach using pharmacophore 
modelling and docking study has successfully 
applied to screen NCI database against MERS-
CoV 3CLpro structure in order to discover new 
inhibitors of MERS-CoV. Using the structure-
based screening approach, five compounds are 
identified as potential agents for the treatment of 
corona virus, MERS-CoV. Binding mode 
analyses reveal that the way these compounds 
bind to MERS-CoV 3CLpro is the same as that of 
the x-ray inhibitor, R30. The results suggest that 
these molecules can possibly be developed as 
novel lead compounds in anti-MERS-CoV drug 
design. 
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